eligibility_summary
Eligibility: Adults ≥18, ECOG 0–1, life expectancy >12 wks, advanced unresectable/metastatic solid tumor refractory/intolerant/no standard therapy, ≥1 RECIST v1.1 target lesion, biopsy-amenable non-irradiated disease and consent for screening/on‑treatment biopsies. Exclude: symptomatic/uncontrolled brain mets, prior CCR8 inhibitor/allergy, live vaccine ≤30 d, pneumonitis, cardiac disease ≤3 mo, recent tx (systemic ≤4 wks, non‑palliative RT ≤2 wks), major surgery ≤4 wks, active infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 1, open-label study in advanced solid tumors. Interventions: 1) ZL-1218 — a monoclonal antibody inhibitor of CCR8 (chemokine receptor). Mechanism: targets CCR8-expressing intratumoral regulatory T cells (Tregs) to block CCR8 signaling and/or deplete CCR8+ Tregs, aiming to relieve immunosuppression in the tumor microenvironment. 2) Pembrolizumab — anti-PD-1 monoclonal antibody checkpoint inhibitor. Mechanism: blocks PD-1 on T cells to restore anti-tumor effector function. Targets/cells/pathways: CCR8+ Tregs in tumors (CCR8 pathway) and the PD-1/PD-L1 checkpoint on activated/exhausted T cells. Tested as ZL-1218 monotherapy and in combination with pembrolizumab.